It is of particular interest that these metabolites may profile mechanisms leading to insulin resistance and vascular disease [36], given that low dose insulin therapy was added to the Milwaukee protocol, version 4, with statistical improvements in survival [44]. This evidence concerns the gene INS and Insulin resistance.